Roberts Wealth Advisors LLC Has $4.06 Million Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Roberts Wealth Advisors LLC raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO – Get Rating) by 1.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 7,341 shares of the medical research company’s stock after buying an additional 127 shares during the quarter. Thermo Fisher Scientific accounts for about 2.0% of Roberts Wealth Advisors LLC’s holdings, making the stock its 11th biggest position. Roberts Wealth Advisors LLC’s holdings in Thermo Fisher Scientific were worth $4,061,000 as of its most recent filing with the SEC.

Several other large investors have also recently added to or reduced their stakes in TMO. Grayhawk Investment Strategies Inc. acquired a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth $26,000. Lowe Wealth Advisors LLC increased its stake in shares of Thermo Fisher Scientific by 160.0% during the 3rd quarter. Lowe Wealth Advisors LLC now owns 52 shares of the medical research company’s stock worth $26,000 after purchasing an additional 32 shares during the last quarter. New Millennium Group LLC acquired a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth $29,000. Toth Financial Advisory Corp increased its stake in shares of Thermo Fisher Scientific by 7,300.0% during the 3rd quarter. Toth Financial Advisory Corp now owns 74 shares of the medical research company’s stock worth $38,000 after purchasing an additional 73 shares during the last quarter. Finally, Coston McIsaac & Partners acquired a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth $44,000. Institutional investors and hedge funds own 85.92% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO traded down $9.75 during midday trading on Friday, reaching $547.34. 1,947,936 shares of the company’s stock were exchanged, compared to its average volume of 1,498,879. The company’s 50 day simple moving average is $565.91 and its two-hundred day simple moving average is $545.06. The firm has a market capitalization of $210.96 billion, a PE ratio of 31.05, a price-to-earnings-growth ratio of 1.88 and a beta of 0.79. Thermo Fisher Scientific Inc. has a 12 month low of $475.77 and a 12 month high of $618.35. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.15 and a current ratio of 1.48.

Thermo Fisher Scientific (NYSE:TMO – Get Rating) last released its quarterly earnings data on Wednesday, February 1st. The medical research company reported $5.40 EPS for the quarter, topping analysts’ consensus estimates of $5.19 by $0.21. The company had revenue of $11.45 billion during the quarter, compared to the consensus estimate of $10.41 billion. Thermo Fisher Scientific had a net margin of 15.47% and a return on equity of 21.42%. The firm’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same period last year, the firm earned $6.54 EPS. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.72 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, April 14th. Investors of record on Wednesday, March 15th will be given a dividend of $0.35 per share. The ex-dividend date of this dividend is Tuesday, March 14th. This represents a $1.40 dividend on an annualized basis and a dividend yield of 0.26%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.30. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 7.94%.

Analysts Set New Price Targets

TMO has been the topic of a number of research analyst reports. Cowen raised their target price on shares of Thermo Fisher Scientific from $690.00 to $711.00 and gave the company an “outperform” rating in a research note on Thursday, February 2nd. Barclays raised their target price on shares of Thermo Fisher Scientific from $630.00 to $660.00 and gave the company an “overweight” rating in a research note on Thursday, February 2nd. Morgan Stanley raised their target price on shares of Thermo Fisher Scientific from $613.00 to $670.00 and gave the company an “overweight” rating in a research note on Thursday, February 2nd. Wells Fargo & Company lowered their target price on shares of Thermo Fisher Scientific from $525.00 to $505.00 and set an “underweight” rating on the stock in a research note on Tuesday, January 3rd. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, December 13th. They issued a “buy” rating and a $620.00 target price on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $647.00.

Insider Buying and Selling

In related news, Director Jim P. Manzi sold 1,000 shares of the stock in a transaction dated Friday, February 3rd. The shares were sold at an average price of $584.56, for a total transaction of $584,560.00. Following the completion of the sale, the director now owns 14,807 shares in the company, valued at approximately $8,655,579.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 1,600 shares of the firm’s stock in a transaction dated Tuesday, February 14th. The shares were sold at an average price of $571.96, for a total value of $915,136.00. Following the completion of the sale, the chief executive officer now owns 128,705 shares in the company, valued at approximately $73,614,111.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jim P. Manzi sold 1,000 shares of the firm’s stock in a transaction dated Friday, February 3rd. The shares were sold at an average price of $584.56, for a total transaction of $584,560.00. Following the completion of the sale, the director now owns 14,807 shares of the company’s stock, valued at approximately $8,655,579.92. The disclosure for this sale can be found here. Insiders sold 30,100 shares of company stock worth $16,966,971 in the last quarter. 0.43% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Company Profile

(Get Rating)

Thermo Fisher Scientific, Inc engages in the provision of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.